Complement activation contributes to the injury and outcome of kidney in human anti-glomerular basement membrane disease

Journal of Clinical Immunology

Volumn 33, Issue 1, 2013, Pages 172-178

  Ma, Rui ^a,b   Cui, Zhao ^a   Liao, Yun Hua ^b   Zhao, Ming Hui ^a,c  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^c Tsinghua University   (China)

Author keywords

Anti glomerular basement membrane disease; Complement; Goodpasture disease; Kidney injury; Outcome

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; CREATININE; MANNOSE BINDING LECTIN; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOLYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GLOMERULONEPHRITIS; GOODPASTURE SYNDROME; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY INJURY; LUNG HEMORRHAGE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; YOUNG ADULT; IMMUNOLOGY; INJURY; KIDNEY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; URINE;

ADOLESCENT; ADULT; AGED; ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; FEMALE; HUMANS; KIDNEY; MALE; MIDDLE AGED; YOUNG ADULT;

MLCS; MLOWN;

EID: 84876453648     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-012-9772-2     Document Type: Article

References (24)

1. Cui Z, Zhao MH, Xin G, Wang HY. Characteristics and prognosis of Chinese patients with anti-glomerular basement membrane disease. Nephron Clin Pract. 2005;99:c49-55.
2. Assmann KJ, Tangelder MM, Lange WP, Schrijver G, Koene RA. Anti-GBM nephritis in the mouse: severe proteinuria in the heterologous phase. Virchows Arch A Pathol Anat Histopathol. 1985;406:285-99.
3. Segelmark M, Hellmark T, Wieslander J. The prognostic significance in Goodpasture's disease of specificity, titre and affinity of anti-glomerular- basement-membrane antibodies. Nephron Clin Pract. 2003;94:c59-68.
4. Fischer EG, Lager DJ. Anti-glomerular basement membrane glomerulonephritis: a morphologic study of 80 cases. Am J Clin Pathol. 2006;125:445-50.
5. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11:785-97.
6. Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res. 2010;20:34-50.
7. Lianos EA. Synthesis of hydroxyeicosatetraenoic acids and leukotrienes in rat nephrotoxic serum glomerulonephritis. Role of anti-glomerular basement membrane antibody dose, complement, and neutrophiles. J Clin Invest. 1988;8:427-35.
8. Shike T, Isome M, Mizuno M, et al. Implication of the complement system in the induction of anti-glomerular basement membrane glomerulonephritis in WKY rats. Pathol Int. 2003;53:757-61.
9. Sheerin NS, Abe K, Risley P, Sacks SH. Accumulation of immune complexes in glomerular disease is independent of locally synthesized c3. J Am Soc Nephrol. 2006;17:686-96.
10. Sheerin NS, Springall T, Abe K, Sacks SH. Protection and injury: the differing roles of complement in the development of glomerular injury. Eur J Immunol. 2001;31:1255-60.
11. Sheerin NS, Springall T, Carroll MC, Hartley B, Sacks SH. Protection against anti-glomerular basement membrane (GBM)-mediated nephritis in C3- and C4-deficient mice. Clin Exp Immunol. 1997;110:403-9.
12. Otten MA, Groeneveld TW, Flierman R, et al. Both complement and IgG fc receptors are required for development of attenuated antiglomerular basement membrane nephritis in mice. J Immunol. 2009;183:3980-8.
13. Chen M, Daha MR, Kallenberg CG. The complement system in systemic autoimmune disease. J Autoimmun. 2010;34:J276-86.
14. Huber-Lang M, Sarma JV, Zetoune FS, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med. 2006;12:682-7.
15. Amara U, Rittirsch D, Flierl M, et al. Interaction between the coagulation and complement system. Adv Exp Med Biol. 2008;632:71-9.
16. Morita Y, Ikeguchi H, Nakamura J, Hotta N, Yuzawa Y, Matsuo S. Complement activation products in the urine from proteinuric patients. J Am Soc Nephrol. 2000;11:700-7.
17. Ogrodowski JL, Hebert LA, Sedmak D, Cosio FG, Tamerius J, Kolb W. Measurement of SC5b-9 in urine in patients with the nephrotic syndrome. Kidney Int. 1991;40:1141-7.
18. Groggel GC, Salant DJ, Darby C, Rennke HG, Couser WG. Role of terminal complement pathway in the heterologous phase of antiglomerular basement membrane nephritis. Kidney Int. 1985;27:643-51.
19. Rauterberg EW, Gehrig T, Kohl P. The attack complex of complement in epimembranous and antibasement membrane antibody glomerulonephritis (abstract). Kidney Int. 1981;20:160.
20. Daina E, Noris M, Remuzzi G. Eculizumab in a patient with densedeposit disease. N Engl J Med. 2012;366:1161-3.
21. Vivarelli M, Pasini A, Emma F. Eculizumab for the treatment of dense-deposit disease. N Engl J Med. 2012;366:1163-5.
22. Radhakrishnan S, Lunn A, Kirschfink M, et al. Eculizumab and refractory membranoproliferative glomerulonephritis. N Engl J Med. 2012;366:1165-6.
23. Pickering MC, Warren J, Rose KL, et al. Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. Proc Natl Acad Sci U S A. 2006;103:9649-54.
24. Huugen D, Esch AV, Xiao H, et al. Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int. 2007;71:646-54.